Rates of Atypical Ductal Hyperplasia Have Declined with Less Use of Postmenopausal Hormone Treatment: Findings from the Breast Cancer Surveillance Consortium

• Published in: Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2009-11, Vol.18 (11), p.2822-2828
• Main Authors: MENES, Tehillah S, KERLIKOWSKE, Karla, JAFFER, Shabnam, SEGER, Deborah, MIGLIORETTI, Diana L
• Format: Article
• Language: English
• Subjects: ADH; Adult; Aged; Aged, 80 and over; atypical ductal hyperplasia; Biological and medical sciences; Breast - pathology; breast cancer; Breast Neoplasms - etiology; Breast Neoplasms - pathology; Breast Neoplasms - prevention & control; Carcinoma, Ductal, Breast - etiology; Carcinoma, Ductal, Breast - pathology; Carcinoma, Ductal, Breast - prevention & control; Estrogen Replacement Therapy; Female; Gynecology. Andrology. Obstetrics; hormone therapy; Humans; Hyperplasia; Lymphatic Metastasis; Mammary gland diseases; Mammography; Medical sciences; Middle Aged; Postmenopause; Prognosis; Risk Factors; Tumors
• ISSN: 1055-9965; 1538-7755
• DOI: 10.1158/1055-9965.EPI-09-0745

Aim: To examine risk factors and rates of atypical ductal hyperplasia (ADH) with and without associated breast cancer over time and tumor characteristics of breast cancer with and without associated ADH in women previously screened with mammography. Methods: Data on screening mammograms done between 1996 and 2005 were collected from mammography registries that participate in the Breast Cancer Surveillance Consortium. Associations between age, family history of breast cancer, postmenopausal hormone treatment (HT), and final pathology result (ADH or cancer with or without ADH in the same breast) were examined. Rates of different outcomes were calculated per exam year. Tumor characteristics of cancers with and without associated ADH were compared. Results: A total of 2,453,483 screening mammograms were associated with 1,064 biopsies with ADH, 833 breast cancers with ADH, and 8,161 cancers with no ADH. Postmenopausal HT use decreased significantly from 35% to 11% during the study period. Rates of ADH decreased from a peak of 5.5/10,000 mammograms in 1999 to 2.4/10,000 in 2005. Rates of cancer with ADH decreased from a peak of 4.3/10,000 mammograms in 2003 to 3.3/10,000 in 2005. ADH and breast cancer were significantly associated with use of postmenopausal HT. Cancer associated with ADH was of lower grade and stage and more estrogen receptor positive than cancer with no ADH. Summary: Postmenopausal HT is associated with an increased risk of ADH with or without cancer. Rates of ADH have decreased over the past decade, which may be partially explained by the significant reduction in use of postmenopausal HT. (Cancer Epidemiol Biomarkers Prev 2009;18(11):2822–8)